Thema: CA05156V1022
AUR, CA05156V1022
money-5338733_1920.jpg - Foto: THN
Aurinia Pharmaceuticals stock gets lift from higher 2026 outlook
Aurinia Pharmaceuticals stock follows results that lifted the company's 2026 revenue outlook. The company is expanding its autoimmune drug pipeline.
ad-hoc-news.de, vor 59 Minuten
AUR, CA05156V1022
Aurinia sets November 3 results. Aurinia Pharmaceuticals ...
Aurinia sets November 3 results with USD 83.61 million expected. Aurinia Pharmaceuticals stock costs EUR 14.87 on October 20, 2026 at 8:44 p.m. CEST.
ad-hoc-news.de, 20.10.26 20:51 Uhr
AUR, CA05156V1022
November 3 earnings carry USD 83.61 million estimate for ...
Aurinia expects USD 0.22 earnings per share for Q3 2026. Aurinia Pharmaceuticals stock costs EUR 14.92 on October 15, 2026, plus 0.72 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 22:28 Uhr
AUR, CA05156V1022
Aurinia Pharmaceuticals stock heads toward its November ...
Aurinia Pharmaceuticals earned USD 0.28 per share in Q2 2026, above the USD 0.19 consensus. Revenue reached USD 83.2 million.
ad-hoc-news.de, 08.10.26 04:39 Uhr
AUR, CA05156V1022
Aurinia reports second-quarter profit growth: what it means ...
